Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ('Alto') (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025.
ALTO-300, also known as agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist being developed at 25mg as an adjunctive treatment in the United States for patients with MDD, characterized by an EEG biomarker. Agomelatine is an approved antidepressant medication at both 25mg and 50mg in Europe and Australia but has not been approved in the United States. In clinical studies, the 50mg dose of agomelatine was associated with low levels of reversible liver enzyme elevations, which were not associated with liver failure. In comparison to the 50mg dose of agomelatine, the 25mg dose has been shown to have similar antidepressant activity while avoiding the rates of liver function test (LFT) elevations associated with the 50mg dose.
'Our ASCP presentation continues to support the unique biomarker opportunity for patient stratification and reinforces the well-established safety and tolerability profile for ALTO-300,' said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. 'Agomelatine has been studied in thousands of patients globally and evidence from meta-analyses and real-world clinical care demonstrates the 25mg dose achieves an optimal balance of antidepressant activity without the concern of LFT elevation. These data are consistent with the positive results from our completed Phase 2a trial, and we are encouraged by the safety and tolerability profile of ALTO-300 in our ongoing Phase 2b trial in patients with major depressive disorder. Taken together, we believe the selected 25mg dose of ALTO-300 is well positioned to demonstrate clinical effects while avoiding the low LFT elevation rates associated with the 50mg dose, which typically occur early, are non-cumulative, resolve quickly, and are not associated with liver failure.'
Summary of Data Presented
ALTO-300 Safety and Tolerability Profile
The most common adverse event observed in the completed Phase 2a trial of ALTO-300 was headache. Additionally, the Phase 2a and Phase 2b trials have involved monitoring for elevated liver enzymes (≥ 3 times the upper limit of normal), with the Phase 2b trial including a stopping rule for elevated liver enzymes. No LFT elevations ≥ 3 times the upper limit of normal were observed in the Company's 239-patient completed Phase 2a trial, and no patients have been stopped in the ongoing Phase 2b trial due to liver enzyme elevation, which remains blinded.
ALTO-300 EEG Biomarker
The ALTO-300 biomarker signal likely reflects increased neural noise due to elevated 5-HT2C tone and reduced dopaminergic activity. Increasing 5-HT2C activity in a preclinical rodent model or directly depleting dopamine in a healthy human volunteer study—both the oppositive mechanistic effect of ALTO-300—resulted in greater EEG irregularity, consistent with a biomarker positive profile. These data reinforce the direct link between ALTO-300 and the EEG biomarker used to identify MDD patients who are more likely to be responders to treatment.
The following poster presented at ASCP 2025 is available under ' Publications ' in the platform section of Alto's website:
ALTO-300 as Adjunctive Treatment for Major Depressive Disorder Supported by Mechanistic Validation of Patient Selection Biomarker and Well-Established Safety and Tolerability Profile
Poster First Author: Michael Avissar, Ph.D.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'expects,' 'plans,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto's expectations about the potential benefits, activity, and effectiveness of its product candidates, biomarkers, and Precision Psychiatry Platform ('Platform'); and Alto's expectations with regard to the design and results of its clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled 'Risk Factors' in Alto's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.
Availability of Information on Alto's Website
Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
How the West Virginia Division of Natural Resources handles nuisance bears
BECKLEY, WV (WVNS) — Now that it is getting warmer, West Virginia's black bears will be out and about looking for food sources to fatten up with for the colder months ahead. Unfortunately, this puts some of them directly in the path of humans. Once again, people are asking if there are mountain lions in the Mountain State Black bears are already starting to eat as much as they can before their next round of hibernation. One resident in Clear Creek found out the hard way; whatever is in their trash bin is on the menu. Samantha Thompson saw a black bear recently. She said she told her neighbors who were already aware of the bear, and they reported it to DNR. DNR set a trap and caught the bear, but what came next shocked Thompson. 'Our understanding was that when they trap the bear, they're gonna take it and relocate it. They're gonna tag it, take it, and relocate it. I was told after the fact that no that was not correct, that most bears, unfortunately, are destroyed rather than being relocated,' said Thompson. Thompson said she was saddened to hear about the death of the bear, commenting that she wishes that the incident had never occurred. This may have you wondering 'why not just release the bear elsewhere?' Colin Carpenter, Black Bear Project Leader for the DNR, said the bears are dispatched for a number of reasons, though they never want to have to harm any of them. 'First being our experience and the scientific literature shows that removing adult bears is typically ineffective. Because their rates of return are higher, they don't do as well in a new environment. So, since 2011, any bear over 140 pounds we have put down, dispatched,' said Carpenter. Carpenter said relocated adult bears will also still try to get back to their home range. They may also find another area populated by humans that has easily accessible food sources as well. He said there is another major reason in play as well. 'Because we have bears everywhere in West Virginia now, you know, thirty years ago when we were moving bears regularly, we didn't have bears in every available habitat. We had places to take them. Now, we have bears statewide. So, moving bears is not a solution to the problem. The solution is addressing the food attractant that's causing the issue,' said Carpenter. How can you help West Virginia's native bats? Carpenter advises everyone to do their own reach on how to live effectively and safely in bear country. He said they never want to dispatch a bear, but that they cannot risk someone being hurt. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
DuPont Powers AI and Next-Gen Electronics with Advanced Interconnect Innovations at JPCA Show 2025
TOKYO, June 3, 2025 /PRNewswire/ -- DuPont (NYSE:DD) today announced its participation in the Total Solution Exhibition for Electronic Equipment 2025 (JPCA Show 2025), taking place from June 4-6 at the Tokyo Big Sight East Exhibition Halls. At Booth #6C-03, DuPont will showcase its extensive portfolio of advanced interconnect solutions, which encompass fine line, signal integrity, power and thermal management. "Our participation at JPCA 2025 underscores our commitment to innovation within the electronics industry," said Yuan Yuan Zhou, Global Business Director, Advanced Circuit & Packaging, Interconnect Solutions. "For over 50 years, we have collaborated with industry leaders to power remarkable advancements in electronics, with a strategic focus on integrate circuit (IC) substrate, advanced printed circuit boards (PCB), and advanced packaging. Our deep customer intimacy, along with the depth and breadth of our technical capabilities, continues to empower advanced computing and connectivity." As artificial intelligence (AI) continues to transform industries, the demand for high-performance IC substrates is surging, with Japan at the forefront of providing innovative materials and processes. These advanced substrates are critical for bridging AI chips and printed circuit boards, enabling quicker data processing and improved thermal management. The global IC substrate market is poised to experience notable growth, driven by the expanding AI ecosystem and the increasing demand for advanced solutions. DuPont's comprehensive solutions empower IC substrate manufacturers to expedite product development and enhance production efficiency. Key offerings include DuPont™ Circuposit™ desmear and electroless copper for mSAP and SAP processes, and DuPont™ Copper Gleam™ electrolytic copper for conformal through-hole plating, which enhances core layer plating technologies. Moreover, DuPont™ Microfill™ acid copper optimizes blind via filling for build-up layers, thereby boosting mSAP and SAP process efficiency. Additionally, DuPont™ Riston® dry film photoresist is essential for a variety of applications, including core and build-up layers, final finishes, and copper pillars. Visitors to DuPont's booth are invited to connect with our experts and discover integrated solutions designed to drive success in the rapidly evolving electronics industry, including our complete range of offerings for PCBs. Circuposit™ SAP8000 electroless copper is an innovative metallization technology designed for AI server CPU and GPU chip applications. This ionic base catalyst process is optimized for advanced packaging, meeting the demands for low roughness dielectrics and low Dk and Df properties, essential for fine line and high-frequency designs. Microfill™ SFP-II-M acid copper offers excellent pattern uniformity, ideal for high-performance computing and AI chip applications. Microfill™ GFH-100 acid copper efficiently fills high aspect ratio through-holes for TGV applications with a unique bridging waveform and one-bath plating. Meanwhile, Microfill™ AHF acid copper supports various hole types in HDI and IC substrates, enabling stacked via structures for simpler processing. Riston® DI1600 and DI1600M dry film photoresists are advanced solutions that enable fine line direct imaging for IC substrate applications. They provide excellent adhesion and resolution, ensuring high-yield performance. Solderon™ TS7000 series solder is a SnAg micro bump plating solution for HBM applications. It offers excellent coplanarity, ideal for mixed and fine pitch micro-bumps, and supports both soluble and insoluble electrode plating solutions for added versatility. CYCLOTENE™ dry-film photo-imageable dielectric (DF-PID) for fan-out panel level package (FOPLP) provides excellent coplanarity through lamination and achieves desired thickness in a single step, unlike liquid dielectrics that require multiple coatings. Additionally, DF-PID for glass core substrate effectively fills through-glass vias (TGV) without voids in glass core substrates, which have successfully passed multi-reflow, biased highly accelerated stress test (bHAST), and high-temperature storage (HTS) reliability tests, showing no delamination or cracking post-assessment. Pyralux® ML laminates are a breakthrough in non-copper-based materials, providing OEMs with a reliable, customizable solution for high-performance markets. By setting a new industry standard and leveraging advanced polyimide technology, these laminates are poised to expand their impact across critical industries, becoming essential for the next generation of electronic and thermal management applications. Pyralux® AP flexible copper-clad laminate is a double-sided laminate featuring an all-polyimide dielectric and a unique manufacturing process. It offers exceptional reliability and reduced transmission loss, meeting customer demands for high-speed, high-frequency signal transmission. About DuPont DuPont (NYSE: DD) is a global innovation leader with technology-based materials and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, healthcare and worker safety. More information about the company, its businesses and solutions can be found at Investors can access information included on the Investor Relations section of the website at DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted. View original content to download multimedia: SOURCE DuPont Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
What a Doctor wants you to know about Measles
SIOUX FALLS, S.D. (KELO) — The South Dakota Department of Health has reported the state's first case of measles in 2025. A man in Meade County developed the infection after traveling internationally. The most common symptoms of measles start off much like a cold, a cough, a runny nose, and red watery eyes, called conjunctivitis. 'That is accompanied by a fever, which is often very high, up to 104 105 degrees. Several days after those symptoms start, 4 or 5 days, is when the characteristic measles rash usually pops up. It's bright red, it starts at the hairline and works its way down the body,' said Doctor Ashley Sands, an infectious disease expert. Remembering The Children Memorial sculpture honors those who lost their lives What makes measles so dangerous is that it can cause pneumonia and encephalitis, which can be fatal. Measles is one of the most contagious infectious diseases known to man. To give you an idea of how contagious measles is, if someone in this room had coughed an hour ago. And if I walk through that airspace, I could become infected if I'm not vaccinated. Dr. Sands says the measles vaccine is very safe and very effective, and has been around since the 1960s. 'We know that with the first dose of measles given around one year of age, that confers around 93 percent immunity, meaning that of 100 people who receive the measles vaccine, 93 will be fully protected for the rest of their lives,' said Dr. Sands. Most people are vaccinated at 12 months old and receive a second dose at age second dose raises a person's protection from 93 percent to 97 in the rare case of a vaccinated person becoming infected, she says the infection is much less severe and contagious. If you are unsure if you were vaccinated as a child, doctors suggest talking with your can also check with your doctor or request your immunization records from the South Dakota Department of Health. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
